Surrozen (SRZN) Change in Accured Expenses (2020 - 2026)
Surrozen (SRZN) recorded quarterly Change in Accured Expenses of -$1.2 million in Q1 2026, down 139.6% quarter-over-quarter from $2.9 million in Q4 2025, and up 2.51% on a YoY basis from -$1.1 million in Q1 2025.
Surrozen (SRZN) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Surrozen's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 2.51% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at $2.5 million (up 152.54% YoY), while the FY2025 annual figure was $2.5 million, up 137.03% from the prior year.
- Change in Accured Expenses was -$1.2 million for Q1 2026 at Surrozen, down from $2.9 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q4 2025 to a low of -$3.8 million in Q1 2022.
- Historically, Change in Accured Expenses has averaged -$113882.4 across 5 years, with a median of $178000.0 in 2023.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses slumped 310.11% in 2022, then jumped 810.81% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $651000.0 in 2022, then plunged by 72.66% to $178000.0 in 2023, then soared by 385.39% to $864000.0 in 2024, then surged by 239.93% to $2.9 million in 2025, then sank by 139.6% to -$1.2 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), $2.9 million (Q4 2025), and $555000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.16 Mn |
| Mar 31, 2026 | -1.16 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 555,000.00 |
| Sep 30, 2025 | 555,000.00 |
| Jun 30, 2025 | 204,000.00 |
| Jun 30, 2025 | 204,000.00 |
| Mar 31, 2025 | -1.19 Mn |
| Mar 31, 2025 | -1.19 Mn |
| Dec 31, 2024 | 864,000.00 |
| Dec 31, 2024 | 864,000.00 |
| Sep 30, 2024 | 674,000.00 |
| Sep 30, 2024 | 674,000.00 |
| Jun 30, 2024 | 658,000.00 |
| Jun 30, 2024 | 658,000.00 |
| Mar 31, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.14 Mn |
| Dec 31, 2023 | 178,000.00 |
| Dec 31, 2023 | 178,000.00 |